Regeneron Pharmaceuticals (REGN) Liabilities and Shareholders Equity (2009 - 2026)

Regeneron Pharmaceuticals' Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $40.9 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 8.85% year-over-year to $40.9 billion; the TTM figure through Mar 2026 stood at $159.8 billion (up 7.38% YoY), while the FY2025 annual figure was $40.6 billion, up 7.41% from the prior year.
• Liabilities and Shareholders Equity was $40.9 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $40.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $40.9 billion in Q1 2026 to a low of $26.3 billion in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $34.1 billion across 5 years, with a median of $34.4 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 48.26% in 2022, then grew 5.91% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $29.2 billion in 2022, then advanced by 13.23% to $33.1 billion in 2023, then gained by 14.15% to $37.8 billion in 2024, then climbed by 7.41% to $40.6 billion in 2025, then gained by 0.76% to $40.9 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $40.9 billion (Q1 2026), $40.6 billion (Q4 2025), and $40.2 billion (Q3 2025), per Business Quant data.